Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Intensive Care Med. 2018 Jul 9;34(5):364–373. doi: 10.1177/0885066618784861

Figure 4. Odds of death with albumin use in septic shock.

Figure 4.

Odds ratios for 90-day mortality are displayed for albumin compared to crystalloid for patients with septic shock. Subgroup analysis of patients with septic shock from the SAFE55 and ALBIOS56 trials suggests a possible mortality benefit with albumin use. In the SAFE study, patients in the albumin group were given 4% albumin rather than crystalloid. In the ALBIOS study, patients in the albumin group were given 20% albumin in addition to crystalloid to maintain a serum level of 30 g/L.